PBA
GTHX

Paradigm Biocapital Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-884,574
Closed -$11M – 30
2022
Q3 		$11M Buy
+884,574
New +$10.1M 1.47% 22

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Paradigm Biocapital Advisors's GTHX Position: Q4 2022 in Review

Paradigm Biocapital Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 884,574 shares — an estimated $11M sold.

Paradigm Biocapital Advisors first reported a position in GTHX in Q3 2022 and held it in 1 quarter. The position peaked at $11M in Q3 2022. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

  • Paradigm Biocapital Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 884,574 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $11M.
  • Paradigm Biocapital Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $11M in Q3 2022.
  • 116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.